View Item 

Show simple item record

Evidence‐based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology
dc.contributor.authorGirolami, Ilaria
dc.contributor.authorLucenteforte, Ersilia
dc.contributor.authorEccher, Albino
dc.contributor.authorMarletta, Stefano
dc.contributor.authorBrunelli, Matteo
dc.contributor.authorGraziano, Paolo
dc.contributor.authorPisapia, Pasquale
dc.contributor.authorMalapelle, Umberto
dc.contributor.authorTroncone, Giancarlo
dc.contributor.authorScarpa, Aldo
dc.contributor.authorHuang, Tao
dc.contributor.authorPantanowitz, Liron
dc.date.accessioned2022-02-07T20:22:06Z
dc.date.available2023-03-07 15:22:05en
dc.date.available2022-02-07T20:22:06Z
dc.date.issued2022-02
dc.identifier.citationGirolami, Ilaria; Lucenteforte, Ersilia; Eccher, Albino; Marletta, Stefano; Brunelli, Matteo; Graziano, Paolo; Pisapia, Pasquale; Malapelle, Umberto; Troncone, Giancarlo; Scarpa, Aldo; Huang, Tao; Pantanowitz, Liron (2022). "Evidence‐based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology." Cancer Cytopathology (2): 96-109.
dc.identifier.issn1934-662X
dc.identifier.issn1934-6638
dc.identifier.urihttps://hdl.handle.net/2027.42/171519
dc.publisherWiley Periodicals, Inc.
dc.subject.otherimmunohistochemistry
dc.subject.othermeta‐analysis
dc.subject.otherpleura
dc.subject.othersystematic review
dc.subject.othereffusion
dc.subject.otherdiagnostic specificity and sensitivity
dc.subject.othercytology
dc.subject.otherbiomarker
dc.subject.othermesothelioma
dc.titleEvidence‐based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171519/1/cncy22509_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171519/2/cncy22509.pdf
dc.identifier.doi10.1002/cncy.22509
dc.identifier.sourceCancer Cytopathology
dc.identifier.citedreferenceRossi ED, Bizzarro T, Martini M, et al. The evaluation of miRNAs on thyroid FNAC: the promising role of miR‐375 in follicular neoplasms. Endocrine. 2016; 54: 723 ‐ 732. doi: 10.1007/s12020‐016‐0866‐0
dc.identifier.citedreferenceWan C, Shen Y‐C, Liu M‐Q, et al. Diagnostic value of fluorescence in situ hybridization assay in malignant mesothelioma: a meta‐analysis. Asian Pac J Cancer Prev. 2012; 13: 4745 ‐ 4749. doi: 10.7314/APJCP.2012.13.9.4745
dc.identifier.citedreferenceEccher A, Girolami I, Lucenteforte E, Troncone G, Scarpa A, Pantanowitz L. Diagnostic mesothelioma biomarkers in effusion cytology. Cancer Cytopathol. Published online January 19, 2021. doi: 10.1002/cncy.22398
dc.identifier.citedreferenceChurg A, Nabeshima K, Ali G, Bruno R, Fernandez‐Cuesta L, Galateau‐Salle F. Highlights of the 14th International Mesothelioma Interest Group Meeting: pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes. Lung Cancer. 2018; 124: 95 ‐ 101. doi: 10.1016/j.lungcan.2018.07.041
dc.identifier.citedreferenceMinato H, Kurose N, Fukushima M, et al. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. Am J Clin Pathol. 2014; 141: 85 ‐ 93. doi: 10.1309/ajcp5knl7qtellyi
dc.identifier.citedreferenceChang S, Oh M‐H, Ji S‐Y, et al. Practical utility of insulin‐like growth factor II mRNA‐binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations. Pathol Int. 2014; 64: 607 ‐ 612. doi: 10.1111/pin.12216
dc.identifier.citedreferenceChurg A, Sheffield BS, Galateau‐Salle F. New markers for separating benign from malignant mesothelial proliferations: are we there yet? Arch Pathol Lab Med. 2016; 140: 318 ‐ 321. doi: 10.5858/arpa.2015‐0240‐SA
dc.identifier.citedreferenceZhong S‐C, Ao X‐J, Yu S‐H. Diagnostic value of GLUT‐1 in distinguishing malignant mesothelioma from reactive mesothelial cells: a meta‐analysis. Biomarkers. 2020; 25: 157 ‐ 163. doi: 10.1080/1354750X.2020.1714735
dc.identifier.citedreferenceYoshimura M, Kinoshita Y, Hamasaki M, et al. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. Lung Cancer. 2019; 130: 187 ‐ 193. doi: 10.1016/j.lungcan.2019.02.004
dc.identifier.citedreferenceShinozaki‐Ushiku A, Ushiku T, Morita S, Anraku M, Nakajima J, Fukayama M. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma. Histopathology. 2017; 70: 722 ‐ 733. doi: 10.1111/his.13123
dc.identifier.citedreferenceChapel DB, Husain AN, Krausz T. Immunohistochemical evaluation of nuclear 5‐hydroxymethylcytosine (5‐hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations. Mod Pathol. 2019; 32: 376 ‐ 386. doi: 10.1038/s41379‐018‐0159‐7
dc.identifier.citedreferenceCreaney J, Robinson BWS. Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment. Chest. 2017; 152: 143 ‐ 149. doi: 10.1016/j.chest.2016.12.004
dc.identifier.citedreferenceCui A, Jin X‐G, Zhai K, Tong Z‐H, Shi H‐Z. Diagnostic values of soluble mesothelin‐related peptides for malignant pleural mesothelioma: updated meta‐analysis. BMJ Open. 2014; 4: e004145. doi: 10.1136/bmjopen‐2013‐004145
dc.identifier.citedreferenceGao R, Wang F, Wang Z, et al. Diagnostic value of soluble mesothelin‐related peptides in pleural effusion for malignant pleural mesothelioma. Medicine (Baltimore). 2019; 98: e14979. doi: 10.1097/MD.0000000000014979
dc.identifier.citedreferencePei D, Li Y, Liu X, et al. Diagnostic and prognostic utilities of humoral fibulin‐3 in malignant pleural mesothelioma: evidence from a meta‐analysis. Oncotarget. 2017; 8: 13030 ‐ 13038. doi: 10.18632/oncotarget.14712
dc.identifier.citedreferenceRen R, Yin P, Zhang Y, et al. Diagnostic value of fibulin‐3 for malignant pleural mesothelioma: a systematic review and meta‐analysis. Oncotarget. 2016; 7: 84851 ‐ 84859. doi: 10.18632/oncotarget.12707
dc.identifier.citedreferenceBerindan‐Neagoe I, del C Monroig P, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014; 64: 311 ‐ 336. doi: 10.3322/caac.21244
dc.identifier.citedreferenceNicolè L, Cappello F, Cappellesso R, VandenBussche CJ, Fassina A. MicroRNA profiling in serous cavity specimens: diagnostic challenges and new opportunities. Cancer Cytopathol. 2019; 127: 493 ‐ 500. doi: 10.1002/cncy.22143
dc.identifier.citedreferenceMcInnes MDF, Moher D, Thombs BD, et al. Preferred Reporting Items for a Systematic Review and Meta‐Analysis of Diagnostic Test Accuracy Studies: the PRISMA‐DTA statement. JAMA. 2018; 319: 388 ‐ 396. doi: 10.1001/jama.2017.19163
dc.identifier.citedreferenceGirolami I, Eccher A, Lucenteforte E, Pantanowitz L. Diagnostic accuracy of immunohistochemical, soluble and molecular markers in the differential diagnosis of malignant mesothelioma from benign mesothelial cells in pleural effusion cytology. PROSPERO International Prospective Register of Systematic Reviews. Published 2020. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=198334
dc.identifier.citedreferenceOuzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016; 5: 210. doi: 10.1186/s13643‐016‐0384‐4
dc.identifier.citedreferenceWhiting PF, Rutjes AWS, Westwood ME, et al. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155: 529 ‐ 536. doi: 10.7326/0003‐4819‐155‐8‐201110180‐00009
dc.identifier.citedreferenceBalshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64: 401 ‐ 406. doi: 10.1016/j.jclinepi.2010.07.015
dc.identifier.citedreferenceMcGrath TA, Alabousi M, Skidmore B, et al. Recommendations for reporting of systematic reviews and meta‐analyses of diagnostic test accuracy: a systematic review. Syst Rev. 2017; 6: 194. doi: 10.1186/s13643‐017‐0590‐8
dc.identifier.citedreferenceAgha MA, El‐Habashy MM, El‐Shazly RA. Role of fibulin‐3 in the diagnosis of malignant mesothelioma. Egypt J Chest Dis Tuberc. 2014; 63: 99 ‐ 105. doi: 10.1016/j.ejcdt.2013.10.004
dc.identifier.citedreferencePass HI, Levin SM, Harbut MR, et al. Fibulin‐3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012; 367: 1417 ‐ 1427. doi: 10.1056/NEJMoa1115050
dc.identifier.citedreferenceBirnie KA, Prêle CM, Musk AWB, et al. MicroRNA signatures in malignant pleural mesothelioma effusions. Dis Markers. 2019; 2019: 8628612. doi: 10.1155/2019/8628612
dc.identifier.citedreferenceCappellesso R, Nicolè L, Caroccia B, et al. Young investigator challenge: microRNA‐21/microRNA‐126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology. Cancer Cytopathol. 2016; 124: 28 ‐ 37. doi: 10.1002/cncy.21646
dc.identifier.citedreferenceYoshimura M, Hamasaki M, Kinoshita Y, et al. Utility of highly expressed EZH2 in pleural effusion cytology for the diagnosis of mesothelioma. Pathol Int. Published online July 29, 2020. doi: 10.1111/pin.12990
dc.identifier.citedreferenceKinoshita Y, Hida T, Hamasaki M, et al. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma. Cancer Cytopathol. 2018; 126: 54 ‐ 63. doi: 10.1002/cncy.21928
dc.identifier.citedreferenceHiroshima K, Wu D, Hamakawa S, et al. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion. Diagn Cytopathol. 2021; 49: 622 ‐ 632. doi: 10.1002/dc.24475
dc.identifier.citedreferenceShahi M, Antic T, Fitzpatrick C, Husain A, Krausz T. A combination of BAP1, 5‐HMC and MTAP immunohistochemical staining in malignant mesothelioma effusions. Mod Pathol. 2020; 33: 420 ‐ 430. doi: 10.1038/s41379‐019‐0354‐1
dc.identifier.citedreferenceChapel DB, Schulte JJ, Berg K, et al. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod Pathol. 2020; 33: 245 ‐ 254. doi: 10.1038/s41379‐019‐0310‐0
dc.identifier.citedreferenceMicolucci L, Akhtar MM, Olivieri F, Rippo MR, Procopio AD. Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta‐analysis. Oncotarget. 2016; 7: 58606 ‐ 58637. doi: 10.18632/oncotarget.9686
dc.identifier.citedreferenceRobinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005; 366: 397 ‐ 408. doi: 10.1016/S0140‐6736(05)67025‐0
dc.identifier.citedreferenceCadby G, Mukherjee S, Musk AW, et al. A genome‐wide association study for malignant mesothelioma risk. Lung Cancer. 2013; 82: 1 ‐ 8. doi: 10.1016/j.lungcan.2013.04.018
dc.identifier.citedreferenceScherpereel A, Opitz I, Berghmans T, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020; 55: 1900953. doi: 10.1183/13993003.00953‐2019
dc.identifier.citedreferenceHenderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of malignant mesothelioma: part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin‐1 and microRNA. J Clin Pathol. 2013; 66: 854 ‐ 861. doi: 10.1136/jclinpath‐2013‐201609
dc.identifier.citedreferenceHjerpe A, Ascoli V, Bedrossian C, et al. Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Cytojournal. 2015; 12: 26. doi: 10.4103/1742‐6413.170726
dc.identifier.citedreferenceNottegar A, Tabbò F, Luchini C, et al. Pulmonary adenocarcinoma with enteric differentiation. Appl Immunohistochem Mol Morphol. 2018; 26: 383 ‐ 387. doi: 10.1097/PAI.0000000000000440
dc.identifier.citedreferenceHusain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018; 142: 89 ‐ 108. doi: 10.5858/arpa.2017‐0124‐RA
dc.identifier.citedreferenceWang L‐M, Shi Z‐W, Wang J‐L, et al. Diagnostic accuracy of BRCA1‐associated protein 1 in malignant mesothelioma: a meta‐analysis. Oncotarget. 2017; 8: 68863 ‐ 68872. doi: 10.18632/oncotarget.20317
dc.identifier.citedreferenceMlika M, Zorgati M, BenKhelil M, El Mezni F. About the diagnostic value of BAP‐1 antibody in malignant pleural mesothelioma: a meta‐analysis. J Immunoassay Immunochem. 2019; 40: 269 ‐ 282. doi: 10.1080/15321819.2019.1574814
dc.identifier.citedreferenceChapel DB, Schulte JJ, Husain AN, Krausz T. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res. 2020; 9 ( suppl 1 ): S3 ‐ S27. doi: 10.21037/tlcr.2019.11.29
dc.identifier.citedreferenceChurg A, Naso JR. The separation of benign and malignant mesothelial proliferations: new markers and how to use them. Am J Surg Pathol. 2020; 44: e100 ‐ e112. doi: 10.1097/PAS.0000000000001565
dc.identifier.citedreferenceWu D, Hiroshima K, Matsumoto S, et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013; 139: 39 ‐ 46. doi: 10.1309/AJCPT94JVWIHBKRD
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncy22509_am.pdf
Size:
1.204MB
Format:
PDF
View/Open
Name:
cncy22509.pdf
Size:
1.643MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.